AVAvalo Therapeutics, Inc. AVTX · NASDAQ
$12.26 -0.81% (-$0.10)
- Market cap
- $657.5M
- Enterprise value
- $572.4M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 11,144.1x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -19.5%
- Gross margin
- -16,861.0%
- Net margin
- -170,056.0%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.79
- Free float
- 89.6%
About the company
Avalo Therapeutics is an American biopharmaceutical company focused on developing medicines for the treatment of cancer and autoimmune diseases. The company specializes in utilizing innovative therapeutic approaches, including immunotherapy and targeted therapy, to identify and treat various types of cancer. Their research and development efforts are aimed at discovering new drug compounds and therapeutic methods that could improve the lives of patients and bring new hope to the field of cancer treatment. Avalo Therapeutics shares could be an interesting choice for investors looking for opportunities in the biotechnology sector and drug development for cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
Garry A. Neil
Employees
33
Headquarters
Wayne
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number